BUZZ — Street View: Grail cancer test's progress boosts prospects for multi — cancer detection market

* Cancer test maker Grail received backing from a panel of outside experts advising the US FDA on Wednesday, setting the stage for a potential landmark approval in screening for the disease * In a 7-2 vote with one abstention, the expert panel concluded that the ability of the test, called Galleri, to catch difficult-to-detect cancers justified its use in adults aged 50 and older * Shares have climbed over 34% since Monday, after FDA staff briefing documents ahead of the panel meeting identified no concerns regarding analytical performance or safety Obvious Positive * Piper Sandler ("Neutral") says it sees the favorable votes across as a "positive for the test Galleri's regulatory path, although the divided effectiveness and benefit-risk votes underscore remaining concerns around clinical benefit" * Says it expects an FDA decision in H1 2027 and sees federal health insurance coverage as the larger gate to broad adoption * RBC Capital Markets ("Sector Perform", PT: $84) says the favorable vote is an obvious positive for Grail, and that Galleri's progress is a tailwind for the entire multi-cancer detection (MCD) category * TD Cowen ("Buy", PT: $88) says the panel's view on Galleri's